We have recently entered the newest phase of myeloma therapies. Initially, classical chemotherapeutic agents/combinations like melphalan and VAD were the standard of care. We then moved into the age of novel therapies with immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), like lenalidomide and bortezomib. We are now entering a time where T-cell redirecting therapies are becoming part of the standard of care. From bispecifics and trispecifics to chimeric antigen receptor T-cells (CAR-Ts); harnessing T-cells to fight myeloma is proving to be one of the most effective approaches to treatment. This collection will look at the available and emerging data from pre-clinical to clinical work, and evaluate this rapidly evolving field.
T-cell redirection therapy is an exciting new frontier in the management of multiple myeloma patients. We are, however, in its infancy, and as such are striving to understand the current and future landscape of not only the therapeutic options, but also the optimal management of the new and complex toxicities.
The scope of this topic will include both clinical and pre-clinical topics focusing on:
- BCMA bispecifics
- non-BCMA bispecifics
- BCMA CAR-T
- non-BCMA CAR-T
- management of cytokine release syndrome (CRS)
- biomarkers of CRS
- predictors of response and resistance to T-cell redirection therapy
- post T-cell redirection therapy phenotype
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Dr. Richter discloses speakers bureau with Janssen, BMS and Sanofi; has participated in advisory boards with Celgene, Janssen, BMS, Karyopharm, Sanofi, X4 pharmaceuticals, Oncopeptides, Adaptive Biotechnologies, Secura bio, AstraZeneca and Takeda, and has participated in consultancy work with BMS, Secura bio and Takeda.
We have recently entered the newest phase of myeloma therapies. Initially, classical chemotherapeutic agents/combinations like melphalan and VAD were the standard of care. We then moved into the age of novel therapies with immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs), like lenalidomide and bortezomib. We are now entering a time where T-cell redirecting therapies are becoming part of the standard of care. From bispecifics and trispecifics to chimeric antigen receptor T-cells (CAR-Ts); harnessing T-cells to fight myeloma is proving to be one of the most effective approaches to treatment. This collection will look at the available and emerging data from pre-clinical to clinical work, and evaluate this rapidly evolving field.
T-cell redirection therapy is an exciting new frontier in the management of multiple myeloma patients. We are, however, in its infancy, and as such are striving to understand the current and future landscape of not only the therapeutic options, but also the optimal management of the new and complex toxicities.
The scope of this topic will include both clinical and pre-clinical topics focusing on:
- BCMA bispecifics
- non-BCMA bispecifics
- BCMA CAR-T
- non-BCMA CAR-T
- management of cytokine release syndrome (CRS)
- biomarkers of CRS
- predictors of response and resistance to T-cell redirection therapy
- post T-cell redirection therapy phenotype
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Dr. Richter discloses speakers bureau with Janssen, BMS and Sanofi; has participated in advisory boards with Celgene, Janssen, BMS, Karyopharm, Sanofi, X4 pharmaceuticals, Oncopeptides, Adaptive Biotechnologies, Secura bio, AstraZeneca and Takeda, and has participated in consultancy work with BMS, Secura bio and Takeda.